Sarepta Therapeutics Inc. SRPT reported on Tuesday that the first-quarter 2025 loss of $3.42 per share was missing the analyst consensus estimate of losses of 95 cents.Quarterly revenue came in at $744.86 million, beating the consensus estimate of $683.36 million.According to Sarepta CEO Doug Ingram, the company also faced headwinds in the quarter. “While we are taking a variety of actions to address and resolve these challenges, we have adjusted our guidance for 2025 to $2.3 billion to $2.6 billion,” Ingra ...

Core Insights - The article does not provide specific insights or analysis regarding any companies or industries, focusing instead on disclaimers and disclosures [1][2] Group 1 - There is no stock, option, or similar derivative position in any of the companies mentioned, nor are there plans to initiate such positions within the next 72 hours [1] - The article expresses personal opinions and is not receiving compensation from any company mentioned [1] - The views expressed may not reflect those of Seeking Alpha as a whole, and the analysts may not be licensed or certified [2]

Core Viewpoint - Sarepta Therapeutics reported a significant adjusted loss in Q1 2025, primarily due to a one-time charge related to a multi-billion-dollar deal with Arrowhead Pharmaceuticals, missing earnings expectations by a wide margin [1][2] Financial Performance - The company recorded total revenues of $744.9 million, an 80% increase year over year, driven by sales of Elevidys, surpassing the Zacks Consensus Estimate of $698.2 million [3] - Product revenues rose 70% year over year to $611.5 million, although this figure fell short of the Zacks Consensus Estimate of $664 million [4] - Elevidys sales generated $375 million, down from $384.2 million in the previous quarter, missing estimates due to safety concerns and site-related constraints [5] - Collaboration and other revenues associated with Elevidys supply to Roche amounted to approximately $133.3 million, significantly up from $54 million in the year-ago period [6] Operating Costs - Adjusted R&D expenses surged to $749.2 million from $178.1 million year over year, reflecting increased costs related to the Arrowhead deal [8] - Adjusted SG&A expenses totaled $107.1 million, a 7% increase year over year, driven by higher professional service expenses [9] Guidance and Market Reaction - Sarepta revised its full-year net product revenue guidance to between $2.3 billion and $2.6 billion, down from a previous forecast of $2.9-$3.1 billion, citing safety concerns and administrative complexities [10] - Following the revised guidance, shares of Sarepta fell 21% in after-hours trading, with a year-to-date decline of 62% compared to a 3% decline in the industry [11] Pipeline Developments - The company is advancing several investigational gene therapies, including SRP-9003 for Limb-girdle muscular dystrophy and SRP-6004 for LGMD type 2B/R2, with data expected in 2025 [17][18] - Sarepta's licensing agreement with Roche for Elevidys allows Roche exclusive rights to market the product in non-U.S. markets, which has implications for revenue generation [7]

Patients can't wait for the next breakthrough in medical research. So neither will we. First Quarter 2025 Financial Results Tuesday, May 6, 2025 MELANIE Living with limb-girdle muscular dystrophy ©SAREPTA THERAPEUTICS, INC. 2025. ALL RIGHTS RESERVED. 1 This presentation includes both GAAP information and Non-GAAP information. Non-GAAP (loss) income is defined as GAAP net (loss) income excluding interest income, net, depreciation and amortization expense, stock-based compensation expense, loss (gain) on stra ...

For the quarter ended March 2025, Sarepta Therapeutics (SRPT) reported revenue of $744.86 million, up 80.2% over the same period last year. EPS came in at -$3.42, compared to $0.73 in the year-ago quarter. The reported revenue represents a surprise of +6.68% over the Zacks Consensus Estimate of $698.2 million. With the consensus EPS estimate being $0.35, the EPS surprise was -1077.14%. While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to ...

Sarepta Therapeutics (SRPT) came out with a quarterly loss of $3.42 per share versus the Zacks Consensus Estimate of $0.35. This compares to earnings of $0.73 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -1,077.14%. A quarter ago, it was expected that this biopharmaceutical company would post earnings of $1.87 per share when it actually produced earnings of $1.50, delivering a surprise of -19.79%.Over the last four quarters ...

Sarepta Therapeutics (SRPT) Q1 2025 Earnings Call May 06, 2025 04:30 PM ET Company Participants Mary Jenkins - Senior Manager of Investor RelationsDouglas Ingram - President & CEODallan Murray - EVP & Chief Customer OfficerLouise Rodino-Klapac - Executive Vice President, Head of R&D and Chief Scientific OfficerIan Estepan - EVP & CFOTazeen Ahmad - MD - US Equity ResearchLouise Chen - Managing DirectorAndrew Tsai - SVPBrian Abrahams - MD & Global Sector Head - Health Care ResearchDebjit Chattopadhyay - Manag ...

Sarepta Therapeutics (SRPT) Q1 2025 Earnings Call May 06, 2025 04:30 PM ET Speaker0 Good afternoon, and welcome to the Sarepta Therapeutics First Quarter twenty twenty five Financial Results Conference Call. As a reminder, today's program is being recorded. At this time, I'll turn the call over to Mary Jenkins, Associate Director, Investor Relations. Please go ahead. Speaker1 Thank you, Marvin, and thank you all for joining today's call. Earlier this afternoon, we released our financial results for the firs ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-14895 SAREPTA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 93-0797222 (State or other juri ...

NEW YORK, May 05, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of  Sarepta Therapeutics, Inc. (“Sarepta” or the “Company”) (NASDAQ: SRPT).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investigation concerns whether Sarepta and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.  [Click here for information about joining the class action] On Ma ...